Open AccessT315I clone selection in a Ph+ all patient under low‐dose ponatinib maintenance
Author(s) -
Noetzli Jasmine,
Gavillet Mathilde,
MasouridiLevrat Stavroula,
Duchosal Michel,
Spertini Olivier
Publication year - 2017
Publication title -
clinical case reports
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.21
H-Index - 9
ISSN - 2050-0904
DOI - 10.1002/ccr3.1032
Subject(s) - ponatinib , medicine , adverse effect , myeloid leukemia , oncology , hematopoietic stem cell transplantation , transplantation , nilotinib , imatinib
Key Clinical Message We report here the clinical course of a Ph+ ALL patient who was treated with ponatinib 15 mg/day, as maintenance therapy, and developed a BCR‐ABL T315I mutation leading to ALL relapse. This clonal evolution was reversed, without adverse effects, by increasing ponatinib to 45 mg/day. To our knowledge, we have been confronted with the first clinical case of a T315I clonal selection of ALL caused by subeffective therapeutic level of the drug. This single patient experience highlights the risk of T315I clone selection in Ph+ ALL treated with reduced dose ponatinib.